Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
VERO US​

(VERO US)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

— Company Profile

Venus Concept Inc. is a medical technology firm that specializes in offering a range of innovative minimally and non-invasive solutions for medical aesthetics and hair restoration. Operating both domestically in the U.S. and internationally, the company is responsible for the development, market introduction, and ongoing provision of these advanced technologies and associated services. Its comprehensive product lineup features several cutting-edge devices: Venus Legacy: A non-invasive system primarily used in dermatological and general surgical procedures for female patients. Venus Versa: A versatile, multi-application platform designed for various aesthetic and cosmetic treatments. Venus Viva: A portable and advanced fractional radiofrequency (RF) system utilized in dermatological procedures for skin ablation and resurfacing. Venus Fiore: Employs non-thermal RF technology, combined with massage and magnetic field pulses, to address a variety of medical conditions. Venus Bliss: Targets non-invasive lipolysis of the abdomen and flanks, suitable for individuals with a body mass index (BMI) of 30 or below. Venus Glow: A specialized dermabrasion device aimed at enhancing overall skin appearance. NeoGraft: Provides advanced hair restoration using an automated Follicular Unit Extraction (FUE) and implantation system. Venus Velocity & Venus Epileve: These devices facilitate permanent hair removal, reduction, and the treatment of pseudofolliculitis barbae. ARTAS iX: A robotic system that assists physicians during hair transplantation by automating the identification, extraction, and implantation of follicular units from the scalp, as well as the creation of recipient sites. The company's corporate headquarters are located in Toronto, Canada.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Rajiv Kanishka Liyanaarchchie De Silva
Headquarters
Toronto, A6, CA
IPO Date
Oct 12, 2017
Employees
292
Website
www.venus.ai

Key Metrics

Price
$0.00
Market Cap
$0.00
Revenue (TTM)
$0.00
Net Income (TTM)
$0.00
EPS (TTM)
0.00
P/E (TTM)
0.00
P/B (TTM)
0.00
Dividend Yield
0.00%
ROE (TTM)
0.00%
ROA (TTM)
0.00%
Operating Margin
0.00%
Beta
0.00

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Venus Concept Inc. is a medical technology firm that specializes in offering a range of innovative minimally and non-invasive solutions for medical aesthetics and hair restoration. Operating both domestically in the U.S. and internationally, the company is responsible for the development, market introduction, and ongoing provision of these advanced technologies and associated services. Its comprehensive product lineup features several cutting-edge devices: Venus Legacy: A non-invasive system primarily used in dermatological and general surgical procedures for female patients. Venus Versa: A versatile, multi-application platform designed for various aesthetic and cosmetic treatments. Venus Viva: A portable and advanced fractional radiofrequency (RF) system utilized in dermatological procedures for skin ablation and resurfacing. Venus Fiore: Employs non-thermal RF technology, combined with massage and magnetic field pulses, to address a variety of medical conditions. Venus Bliss: Targets non-invasive lipolysis of the abdomen and flanks, suitable for individuals with a body mass index (BMI) of 30 or below. Venus Glow: A specialized dermabrasion device aimed at enhancing overall skin appearance. NeoGraft: Provides advanced hair restoration using an automated Follicular Unit Extraction (FUE) and implantation system. Venus Velocity & Venus Epileve: These devices facilitate permanent hair removal, reduction, and the treatment of pseudofolliculitis barbae. ARTAS iX: A robotic system that assists physicians during hair transplantation by automating the identification, extraction, and implantation of follicular units from the scalp, as well as the creation of recipient sites. The company's corporate headquarters are located in Toronto, Canada.

Website
www.venus.ai
Location
Toronto, A6, CA
Phone18778488430
Employees292
CEORajiv Kanishka Liyanaarchchie De Silva
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateOct 12, 2017

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(752)

Expand
  • DRule 506(b) provides a "safer harbor" for a private offering9 Apr
  • SC 13D/AVenus Concept Inc.1 Apr
  • SC 13D/AVenus Concept Inc.30 Mar
  • 4Statement of changes in beneficial ownership30 Mar
  • 4Statement of changes in beneficial ownership27 Mar
  • SC 13D/AVenus Concept Inc.27 Mar
  • SC 13D/AVenus Concept Inc.18 Mar
  • SC 13D/AVenus Concept Inc.17 Mar
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb
  • EFFECTNotice of effectiveness11 Feb

News

  • Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada28 Jul

Mentions in Filings

  • … ##### Table of Contents | | | | | | | --- | --- | --- | --- | --- | | **Closed Date** | **Surviving Company** | **Public Company** | **Value Delivered for Public Vehicle8 Net of Cash ($M)** | | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | | 9/27/2019 | Ocugen, Inc. | Histogenics Corporation (NASDAQ: HSGX) | | NA | | 8/31/2019 | Brickell Biotech, Inc. | Vical Incorporated (NASDAQ: VICL) | | 4 | | 7/31/2019 …
    Sonic Holdco, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·16 Oct
  • … OPGN) | | 7 | | 1/9/2020 | Protara Therapeutics, Inc. | Proteon Therapeutics, Inc. (NASDAQ: PRTO) | | 5 | | 12/30/2019 | NeuroBo Pharmaceuticals, Inc. | Gemphire Therapeutics Inc. (NASDAQ: GEMP) | | 8 | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | | 9/27/2019 | Ocugen, Inc. | Histogenics Corporation (NASDAQ: HSGX) | | NA | | 8/31/2019 | Brickell Biotech, Inc. | Vical Incorporated (NASDAQ: VICL) | | 4 | | …
    Boundless Bio, Inc.·S-4 - Registration statement (business combination)·Q4 26·8 Oct
  • … OPGN) | | 7 | | 1/9/2020 | Protara Therapeutics, Inc. | Proteon Therapeutics, Inc. (NASDAQ: PRTO) | | 5 | | 12/30/2019 | NeuroBo Pharmaceuticals, Inc. | Gemphire Therapeutics Inc. (NASDAQ: GEMP) | | 8 | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | | 9/27/2019 | Ocugen, Inc. | Histogenics Corporation (NASDAQ: HSGX) | | NA | | 8/31/2019 | Brickell Biotech, Inc. | Vical Incorporated (NASDAQ: VICL) | | 4 | | …
    InMed Pharmaceuticals Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q2 27·1 Oct
  • … OPGN) | | 7 | | 1/9/2020 | Protara Therapeutics, Inc. | Proteon Therapeutics, Inc. (NASDAQ: PRTO) | | 5 | | 12/30/2019 | NeuroBo Pharmaceuticals, Inc. | Gemphire Therapeutics Inc. (NASDAQ: GEMP) | | 8 | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | | 9/27/2019 | Ocugen, Inc. | Histogenics Corporation (NASDAQ: HSGX) | | NA | | 8/31/2019 | Brickell Biotech, Inc. | Vical Incorporated (NASDAQ: VICL) | | 4 | | …
    InMed Pharmaceuticals Inc.·S-4/A - Registration statement (business combination, amendment)·Q1 27·29 Sep
  • … ##### Table of Contents | | | | | | | --- | --- | --- | --- | --- | | **Closed Date** | **Surviving Company** | **Public Company** | **Value Delivered for Public Vehicle8 Net of Cash ($M)** | | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | | 9/27/2019 | Ocugen, Inc. | Histogenics Corporation (NASDAQ: HSGX) | | NA | | 8/31/2019 | Brickell Biotech, Inc. | Vical Incorporated (NASDAQ: VICL) | | 4 | | 7/31/2019 …
    Sonic Holdco, Inc.·S-4 - Registration statement (business combination)·Q3 26·10 Sep
  • … /18/2020 | Timber Pharmaceuticals, Inc. | BioPharmX Corporation (AMEX: BPMX) | | 16 | | 4/1/2020 | Curetis NV (Euronext: CURE) | OpGen, Inc. (NasdaqCM: OPGN) | | 7 | | 1/9/2020 | Protara Therapeutics, Inc. | Proteon Therapeutics, Inc. (NASDAQ: PRTO) | | 5 | | 12/30/2019 | NeuroBo Pharmaceuticals, Inc. | Gemphire Therapeutics Inc. (NASDAQ: GEMP) | | 8 | | 11/7/2019 | <strong>Venus Concept</strong> Ltd. | Restoration Robotics, Inc. (NASDAQ: HAIR) | | 20 | 174 ---
    InMed Pharmaceuticals Inc.·S-4/A - Registration statement (business combination, amendment)·Q1 27·9 Sep

Key Stats

Trading

Px/Chg 1D$0.00 / +0.00%
52 Wk H$0.00
52 Wk L$0.00
Avg Volume0.00
Beta0.00
Mkt Cap0.00

Float

Shrs Out/Float1.86M / 1.62M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$0.00

Current Valuation

EV27.20M
EV/EBITDA-0.60
EV/Sales0.46
P/B0.00
P/S0.00
FCF Yield0.00%
ROE0.00%
ROA0.00%
Current Ratio0.00

Estimates

P/E0.00
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '22May '23May '24May '25Apr '26
PRICE-BASED RATIOS
Price / Earnings-4.67-17.49-4.74-1.04-0.04-0.03
Price / Sales1.293.812.080.510.030.04
Price / Book Value6.729.8325.58-2.760.730.22
Price / Free Cash Flow-6.14-19.85-7.58-2.98-0.15-0.12
ENTERPRISE VALUE METRICS
Enterprise Value182.5450.2279.9113.640.927.8
Enterprise Value / Sales2.244.262.811.490.632.02
Enterprise Value / EBITDA-9.87-34.53-7.93-4.35-1.14-1.40
Enterprise Value / EBIT-7.66-25.16-7.04-3.76-1.03-1.34

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '20Dec '21Dec '22Dec '23Dec '24
INCOME STATEMENT
Revenue-4.5%78.0105.699.576.464.8
Gross Income-3.6%51.474.166.052.244.3
EBITDA-14.8%-68.5-13.0-35.3-26.1-36.0
EBIT-14.1%-73.3-17.9-39.7-30.2-39.9
Net Income-12.9%-81.7-23.0-43.7-37.3-47.0
EPS (Diluted)18.2%-33.92-6.34-9.91-6.84-66.28
BALANCE SHEET
Cash & ST Inv-40.6%34.330.911.65.44.3
Total Assets-19.3%160.5157.4125.493.768.2
Total Liabilities-13.5%116.8115.8116.6107.165.3
Total Shareholder Equity-51.9%44.240.98.1-14.02.4
CASH FLOW
Net Operating Cash Flow-21.2%-28.7-19.8-27.0-12.9-11.1
Cap Ex-19.4%-0.3-0.5-0.3-0.1-0.1
Free Cash Flow-21.1%-28.9-20.3-27.3-13.0-11.2

Segment data

Revenue

by Products and services

  • System59%
  • Leases20%
  • Product16%
  • Service5%

Revenue

by Geography

  • United States59%
  • Non-us41%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN